Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus PLENDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus PLENDIL.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs PLENDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker